Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer

Publisher： Spandidos Publications

E-ISSN： 1791-2423|46|3|1025-1030

ISSN： 1019-6439

Source： International Journal of Oncology, Vol.46, Iss.3, 2015-03, pp. : 1025-1030

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ALK inhibitors and advanced non-small cell lung cancer (Review)

By                  

International Journal of Oncology, Vol. 45, Iss. 2, 2014-01 ,pp. : 499-508

Spandidos Publications

Access to resources Recommend Favorite

Erratum to: Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin’s lymphoma, and neuroblastoma

By Morales La Madrid Andres   Campbell Nicholas   Smith Sonali   Cohn Susan   Salgia Ravi  

Targeted Oncology, Vol. 8, Iss. 4, 2013-12 ,pp. : 301-301

Springer Publishing Company

Access to resources Recommend Favorite

Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition

By                          

International Journal of Oncology, Vol. 45, Iss. 4, 2014-01 ,pp. : 1430-1436

Spandidos Publications

Access to resources Recommend Favorite

A case of ALK-associated non-small-cell lung cancer with evidence of omental metastasis 6 years after initial presentation

By Kulkarni Sameer   Kabbinavar Fairooz   Eshaghian Shahrooz  

Lung Cancer Management, Vol. 2, Iss. 3, 2013-06 ,pp. : 199-204

Future Medicine

Access to resources Recommend Favorite

EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 11, Iss. 4, 2016-11 ,pp. : 393-400

Bentham Science Publishers

Access to resources Recommend Favorite